公开(公告)号：US20210109113A1

公开(公告)日：2021-04-15

申请号：US17046430

申请日：2019-04-11

Applicant: KONINKLIJKE PHILIPS N.V.

Inventor： Gerben KOOIJMAN ,  Amir Hussein RMAILE ,  Carl GLASSE ,  Marinus Karel Johannes DE JAGER ,  Iain Leslie Campbell CHAPPLE ,  Melissa Mackay GRANT ,  Philip PRESHAW ,  John J. TAYLOR ,  Michael Alex VAN HARTSKAMP

IPC: G01N33/68 ,  G01N33/573 ,  G16H50/20 ,  G16H50/30

Abstract: Disclosed is an in vitro method for assessing whether a human patient has periodontitis. The method is based on the insight to determine biomarker proteins. Accordingly, in a sample of saliva a patient suffering from periodontitis, the concentrations are measured of two or more of the proteins Matrix metalloproteinase-8 (MMP-8), Matrix metalloproteinase-9 (MMP-9), Pyruvate Kinase (PK) and S100 calcium-binding protein A8 (S100A8). Based on the concentrations as measured, a value is determined reflecting the joint concentrations for said proteins. This value is compared with a threshold value reflecting in the same manner the joint concentrations associated with periodontitis. The comparison allows assessing whether the testing value is indicative of the presence of periodontitis in said patient. Thereby, typically, a testing value reflecting a joint concentration below the joint concentration reflected by the threshold value is indicative for absence of periodontitis in said patient, and a testing value reflecting a joint concentration at or above the joint concentration reflected by the threshold value, is indicative for periodontitis in said patient.

公开(公告)号：US20230393149A1

公开(公告)日：2023-12-07

申请号：US18236453

申请日：2023-08-22

Applicant: KONINKLIJKE PHILIPS N.V.

Inventor： Gerben KOOIJMAN ,  Michael Alex VAN HARTSKAMP ,  Marinus Karel Johannes DE JAGER ,  Amir Hussein RMAILE ,  Philip PRESHAW ,  John J. TAYLOR

IPC: G01N33/68 ,  G16H10/40

CPC classification number: G01N33/6893 ,  G16H10/40 ,  G01N2333/4737 ,  G01N2333/4753 ,  G01N2333/545 ,  G01N2800/18 ,  G01N2800/60

Abstract: Disclosed is an in vitro method for assessing the presence of gingivitis in a human subject. The method is based on the insight to determine a selection of three biomarker proteins. Accordingly, in a saliva sample of the subject the concentrations are measured of the proteins Hepatocyte growth factor (HGF) and Interleukin-1β (IL-1β), and at least one of C reactive protein (CRP) and Haemoglobin. Based on the concentrations as measured, a value is determined reflecting the joint concentrations for said proteins. This value is compared with a threshold value reflecting in the same manner the joint concentrations associated with the absence of gingivitis or periodontitis. The comparison allows to assessing whether the testing value is indicative of the presence of gingivitis in said subject. Thereby, typically, a testing value reflecting a joint concentration above the joint concentration reflected by the threshold, is indicative of the presence of gingivitis.